Pegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B

Date
2007
Author
Gurel, Selim
Ersoz, Galip
Ozenirler, Seren
Kalayci, Cem
Poturoglu, Sule
Kaymakoglu, Sabahattin
Okten, Atilla
Cakaloglu, Yilmaz
Oguz, Dilek
Gur, Gurden
Tankurt, Ethem
Metadata
Show full item record
Abstract
Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of < 400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.
URI
http://hdl.handle.net/20.500.12627/40045
https://doi.org/10.1128/aac.00088-07
Collections